AZD5363 is an orally active, selective protein kinase B (PKB, also known as Akt) inhibitor derived from a collaborative drug discovery program between AstraZeneca, Astex Pharmaceuticals™, The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT). The program began in 2003 through Astex Pharmaceuticals¡¯ collaboration with ICR and CRT, and AstraZeneca¡¯s collaboration with Astex Pharmaceuticals on a drug discovery program targeting PKB/Akt began in 2005. Inhibition of the PKB/Akt pathway has potential in the treatment of a broad range of tumor types. In April 2011 AstraZeneca announced that it had commenced a phase 1 study of AZD5363 in patients with advanced solid tumors.

June 21, 2017

prudect name : AZD5363 is an orally active, selective protein kinase B (PKB, also known as Akt) inhibitor derived from a collaborative drug discovery program between AstraZeneca, Astex Pharmaceuticals™, The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT). The program began in 2003 through Astex Pharmaceuticals¡¯ collaboration with ICR and CRT, and AstraZeneca¡¯s collaboration with Astex Pharmaceuticals on a drug discovery program targeting PKB/Akt began in 2005. Inhibition of the PKB/Akt pathway has potential in the treatment of a broad range of tumor types. In April 2011 AstraZeneca announced that it had commenced a phase 1 study of AZD5363 in patients with advanced solid tumors.
AZD5363

Synonyms: CAS NO: 1143532-39-1Molecular Formula: C₂₁H₂₅ClN₆O₂Molecular Weight: 428.17275 Purity: 98% minSolubility: In DMSOStorage: −20°C

199596-05-9 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1850093